Download by
Scanning QR Code
No Stock Yet
Loading...
No Stock Yet
No Data
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. The spread of the monkey pox virus i
Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and m
AxoGen, Better Therapeutics top healthcare gainers; Nephros, BioAtla lead losers' pack
Gainers: AxoGen (AXGN) +26%. Better Therapeutics (BTTX) +15%. Intercept Pharmaceuticals (ICPT) +13%. XORTX Therapeutics (XRTX) +13%. Belite Bio (BLTE) +8%. Losers: Nephros (NEPH) -32%. BioAtla (BCA
Belite Bio Presented Interim Results Of LBS-008 Phase 1b/2 Study In Adolescent STGD1 At ARVO Annual Meeting 2022
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjects A trend for stabilized or improved visual acuity was observedObserved adverse events were
Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022
LBS-008 (aka Tinlarebant) showed an acceptable safety profile in adolescent Stargardt disease (STGD1) subjectsA trend for stabilized or improved visual acuity was observedObserved adverse events were
Belite Bio Shares Rise for Second Day, Up 9%
By Chris Wack Belite Bio Inc. shares rose for the second day in a row Wednesday, one day after the company said a retinal-disease drug was granted U.S. Food and Drug Administration fast-track
Bright Health, TransMedics top healthcare gainers; Connect Biopharma, Amarin lead losers' pack
Gainers: Bright Health Group (BHG) +21%. TransMedics Group (TMDX) +21%. Belite Bio (BLTE) +11%. Sharps Technology (STSS) +11%. Immutep (IMMP) +7%. Losers: Connect Biopharma (CNTB) -45%. Amarin (AMRN
Belite Bio Announces Closing of $36 Million Initial Public Offering
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite" or the "Company"), a clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases such as dry AMD and Stargardt disease, and m
Belite Bio IPO of 6 M Amer Depositary Shrs Closed at Price Per ADS of $6 >BLTE
Belite Bio IPO of 6 M Amer Depositary Shrs Closed at Price Per ADS of $6 >BLTE
12 Health Care Stocks Moving In Tuesday's Intraday Session
 Gainers Blue Water Vaccines (NASDAQ:BWV) stock increased by 47.0% to $4.91 during Tuesday's regular session. The current volume of 5.4 million shares is 811.1% of Blue Water Vaccines's average full